MedVasc has closed an investment round of 3 M SEK. The investors include several Life science investors such as Life Science Invest Gamma, but also existing and new private investors.
The raised capital will mainly be used for final product development and for preparing an FDA 510k application for the company’s anesthesia catheter SolutioTM. SolutioTM minimizes the pain of implementing the golden standard methods for the treatment of varicose veins and is expected to reach the American market in 2025.
“We note that in a short time, we managed to attract the funds to reach relevant milestones for the coming developments goal for our Solutio ™ catheter.It feels very good that we are now expanding our ownership group with new investors who are specialized in Life Science”, says the company’s CEO, Cathrin Johansson.